BSX - Boston Scientific

The FDA panel was split but went with no restrictions for off label use of drug coated stents. Word of the decision came late in the session. The bias in after hours has been mildly positive. We started to lighten up on our call position late in the day on Friday, and we'll see next week if at some point we get the chance to lighten further either at a loss, or at a profit, or if we get trapped in a zero bid situation.